0000000000643220

AUTHOR

Veronique Schmitt

showing 2 related works from this author

Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura

2017

BACKGROUND Thrombotic thrombocytopenic purpura (TTP) is an acute life-threatening microangiopathy with a tendency of relapse characterized by consumptive thrombocytopenia, microangiopathic hemolytic anemia, and spontaneous von Willebrand factor–induced platelet clumping leading to microthrombi. The brain is frequently affected by microthrombi leading to neurologic abnormalities of varying severity. STUDY DESIGN AND METHODS The aim of this observational cohort study was to investigate the prevalence of depression and cognitive deficits in 104 patients having survived acute TTP. TTP survivors were repeatedly assessed by means of different standardized questionnaires to evaluate depression (ID…

Pediatricsmedicine.medical_specialtybusiness.industryImmunologyMicroangiopathyThrombotic thrombocytopenic purpuraCognitionHematologyMicroangiopathic hemolytic anemia030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesImmunology and AllergyMedicineEffects of sleep deprivation on cognitive performanceYoung adultbusinessDepression (differential diagnoses)030215 immunologyCohort studyTransfusion
researchProduct

Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab.

2018

Background Autoimmune thrombotic thrombocytopenic purpura (iTTP) is caused by autoantibody-mediated severe a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13) deficiency leading to micro-angiopathic haemolytic anaemia (MAHA) and thrombocytopenia with organ damage. Patients survive with plasma exchange (PEX), fresh frozen plasma replacement and corticosteroid treatment. Anti-CD20 monoclonal antibody rituximab is increasingly used in patients resistant to conventional PEX or relapsing after an acute bout. Objective This retrospective observational study focused on the relapse rate and possible influencing factors including treatment with rituximab first…

AdultMalemedicine.medical_specialtyAdolescentautoantibodiesThrombotic thrombocytopenic purpuraADAMTS13 ProteinRelapse rate030204 cardiovascular system & hematologyGastroenterologyAutoimmune Diseases03 medical and health sciencesYoung Adult0302 clinical medicineSex FactorsRecurrenceInternal medicinehemic and lymphatic diseasesCellular Haemostasis and PlateletsMedicineHumansImmunologic Factorsclinical studiesYoung adultChildADAMS/ADAMTS13Retrospective StudiesPurpura Thrombotic Thrombocytopenicbusiness.industryRetrospective cohort studyHematologythrombotic thrombocytopenic purpura (TTP/HUS)Middle Agedmedicine.diseaseAntigens CD20ADAMTS13PurpuraTreatment Outcome030220 oncology & carcinogenesisRituximabFemaleFresh frozen plasmamedicine.symptombusinessRituximabmedicine.drugFollow-Up StudiesThrombosis and haemostasis
researchProduct